However, I think Cytodyn Mgmt is more savvy than t

Quote:

---

However, I think Cytodyn Mgmt is more savvy than the Armchair CEOs would give them credit for

---

Dr.NP emphatically boasted on at least 4 or 5 different occasions, stretching over a period of 2 months, that he could call for an interim look at the Phase 3 S/C trial at 50 patients.

This was patently untrue. The interim look at the S/C trial could only take place at 50% of the 390 patients defined in the protocol -- which is 195 patients. And we are at least 6-8 weeks away from achieving that threshold, if not more.

Not a single member of the Management Team, not a single member of the Board of Directors, and not a single individual from the CRO Amarex either understood that this assertion was blatantly wrong -- or took the time to correct him.

And it wasn't until earlier this month that investors learned that this statement was not true.

I really hope that Cytodyn Management is more savvy than us Armchair CEOs.